SG11202112827QA - Imidazolo derivatives, compositions and methods as orexin antagonists - Google Patents

Imidazolo derivatives, compositions and methods as orexin antagonists

Info

Publication number
SG11202112827QA
SG11202112827QA SG11202112827QA SG11202112827QA SG11202112827QA SG 11202112827Q A SG11202112827Q A SG 11202112827QA SG 11202112827Q A SG11202112827Q A SG 11202112827QA SG 11202112827Q A SG11202112827Q A SG 11202112827QA SG 11202112827Q A SG11202112827Q A SG 11202112827QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
orexin antagonists
imidazolo
derivatives
Prior art date
Application number
SG11202112827QA
Other languages
English (en)
Inventor
Belew Mekonnen
Hemantbhai Patel
Original Assignee
Hager Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hager Biosciences Llc filed Critical Hager Biosciences Llc
Publication of SG11202112827QA publication Critical patent/SG11202112827QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202112827QA 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists SG11202112827QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856830P 2019-06-04 2019-06-04
PCT/US2020/035848 WO2020247445A1 (en) 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists

Publications (1)

Publication Number Publication Date
SG11202112827QA true SG11202112827QA (en) 2021-12-30

Family

ID=73652477

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112827QA SG11202112827QA (en) 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists

Country Status (9)

Country Link
US (1) US20220259224A1 (ja)
EP (1) EP3972588A4 (ja)
JP (1) JP2022534704A (ja)
KR (1) KR20220016918A (ja)
CN (1) CN114286675A (ja)
AU (1) AU2020286381A1 (ja)
CA (1) CA3140170A1 (ja)
SG (1) SG11202112827QA (ja)
WO (1) WO2020247445A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534709A (ja) * 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのピラゾール及びイミダゾール誘導体、組成物、並びに方法
BR112022011917A2 (pt) 2019-12-20 2022-09-06 Tenaya Therapeutics Inc Fluoroalquil-oxadiazois e seus usos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
AU2003262516A1 (en) * 2002-09-18 2004-04-08 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
CN101627028B (zh) * 2006-12-01 2013-03-27 默沙东公司 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
RU2013123035A (ru) * 2010-10-21 2014-11-27 Байер Интеллекчуал Проперти Гмбх 1-(гетероциклический карбонил) 2-замещенные пирролидины
WO2012110986A1 (en) * 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016031815A1 (ja) * 2014-08-26 2016-03-03 武田薬品工業株式会社 複素環化合物
JP2022534709A (ja) * 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのピラゾール及びイミダゾール誘導体、組成物、並びに方法

Also Published As

Publication number Publication date
WO2020247445A1 (en) 2020-12-10
AU2020286381A1 (en) 2022-01-20
CA3140170A1 (en) 2020-12-10
EP3972588A4 (en) 2023-05-31
KR20220016918A (ko) 2022-02-10
CN114286675A (zh) 2022-04-05
US20220259224A1 (en) 2022-08-18
EP3972588A1 (en) 2022-03-30
JP2022534704A (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
IL286077A (en) Carboxamide-pyrimidine history and their use as shp2 antagonists
IL286998A (en) Pyrimidinone history and their use as shp2 antagonists
EP3829581C0 (en) PYRIDONE A2R ANTAGONISTS
IL280809B (en) New preparations, their use and methods of their creation
SG11202112828SA (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
GB2578519B (en) Compositions and methods and uses relating thereto
GB201901099D0 (en) Methods, uses and compositions
IL292692A (en) mrgprx2 antagonists and their uses
GB201905552D0 (en) Antagonists
GB202017595D0 (en) Compositions, and methods and uses relating thereto
IL272952A (en) Modified derivatives of 2-aza-bicyclo[3.1.1]-heptane and 2-aza-bicyclo[3.2.1]-octane as orexin receptor blockers
GB2576614B (en) Compositions, uses and methods
GB202017593D0 (en) Compositions and methods and uses relating thereto
GB201815402D0 (en) Compositions and methods and uses relating thereto
EP3774739A4 (en) CONDENSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONISTS
IL286587A (en) Preparations of d-methyrosine and methods for their preparation
SG11202112827QA (en) Imidazolo derivatives, compositions and methods as orexin antagonists
GB201804163D0 (en) Uses, compositions and methods
IL287120A (en) Compounds, preparations and methods
IL292693A (en) mrgprx2 antagonists and their uses
EP3665165A4 (en) DHFR INHIBITORS, ASSOCIATED COMPOSITIONS AND PROCESSES
ZA202104192B (en) Mmpl3 inhibitors, compositions and uses thereof
EP3853230A4 (en) CDPK1 INHIBITORS, COMPOSITIONS AND METHODS THEREFOR
GB201901413D0 (en) Compositions and their use
GB2586313B (en) Compositions and methods and uses relating thereto